Drugs / Ultevursen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06627179 | Dec 2024 → Jul 2028 expected | Usher syndrome type 2, retinitis pigmentosa, vision disorder | Laboratoires Thea | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05158296 | Dec 2021 → Oct 2022 | Usher syndrome type 2, retinitis pigmentosa, vision disorder | Laboratoires Thea | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Théa Open Innovation, France | Sepul Bio completes LUNA Phase 2b trial enrollment for Ultevursen thea.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultevursen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05158296 ↗ |
| Modality | Antisense oligonucleotide | “RNA antisense oligonucleotide for intravitreal injection” NCT05158296 ↗ |
| Route | Intravitreal | “ultevursen administered via intravitreal injection (IVT)” NCT05158296 ↗ |